The new research
The aim of the study is to demonstrate the performance of the neuCA15.3 test for monitoring treatment response and/or disease recurrence compared to an FDA cleared CA15-3 test (Roche Elecys CA15-3 II).
Is anyone expecting any significantly different data - we've already been told specificity and sensitivity %'s - what exactly will the new study tell us?
Ann: Trading Halt, page-12
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.5¢ |
Change
0.010(1.80%) |
Mkt cap ! $50.61M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 56.5¢ | 54.0¢ | $137.8K | 249.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3475 | 55.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 2934 | 2 |
View Market Depth
| Last trade - 15.27pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
56.0¢ |
Change
0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 55.0¢ | 56.0¢ | 54.5¢ | 14059 | ||
| Last updated 14.17pm 06/06/2024 ? | |||||
| IIQ (ASX) Chart |